Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Double-blind, Randomised Study to Assess the Influence of Tiotropium (Spiriva®)

Phase 1

Completed

Conditions: Healthy

First Posted Date: 2005-11-23

Last Posted Date: 2013-11-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 56

Registration Number: NCT00257452

Locations: 🇩🇪
Humanpharmakologisches Zentrum, Ingelheim/Rhein, Germany

Study to Evaluate the Trough and Peak Effect of Once Daily Telmisartan 80 mg/Hydrochlorothiazide 12.5 mg (Micardis Plus) by Ambulatory Blood Pressure Monitoring (ABPM) in Patients With Mild to Moderate Essential Hypertension

Phase 3

Completed

Conditions: Hypertension

First Posted Date: 2005-11-23

Last Posted Date: 2013-11-11

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 29

Registration Number: NCT00257491

Locations: 🇨🇳
Shanghai Ruijin Hospital, Shanghai, China

A Study of BIBR 1048 in Prevention of Venous Thromboembolism in Patients With TKR Surgery.

Phase 2

Completed

Conditions: Arthroplasty, Replacement, Knee
Venous Thrombosis

Interventions: Drug: placebo
Drug: Dabigatran Etexilate

First Posted Date: 2005-10-30

Last Posted Date: 2014-06-09

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 512

Registration Number: NCT00246025

Locations: 🇯🇵
1160.50.030 Boehringer Ingelheim Investigational Site, Okayama, Okayama, Japan
🇯🇵
1160.50.015 Boehringer Ingelheim Investigational Site, Osaka, Osaka, Japan
🇯🇵
1160.50.016 Boehringer Ingelheim Investigational Site, Osaka, Osaka, Japan

and more 35 locations

Blood Pressure Reduction in Danish General Practice (BRIDGE)

Phase 4

Completed

Conditions: Hypertension

First Posted Date: 2005-10-27

Last Posted Date: 2008-01-21

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1000

Registration Number: NCT00244660

Locations: 🇩🇰
Frederiksberg Hospital, Frederiksberg F, Denmark

Phase IV, 9 Weeks Comparison Between MICARDIS 80 mg and Amlodipine 10 mg on Biological PPAR Gamma Activities

Phase 4

Completed

Conditions: Metabolic Syndrome X
Hypertension

First Posted Date: 2005-10-21

Last Posted Date: 2023-12-08

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 100

Registration Number: NCT00242814

Locations: 🇫🇷
502.486.3302A Cabinet Médical, Angers, France
🇫🇷
502.486.3323A Cabinet Médical, Angers, France
🇫🇷
502.486.3307A Cabinet Médical, Chemille, France

and more 28 locations

Investigation of Safety, Tolerability and Maximum Tolerated Dose (MTD) of BI 2536 in Patients With Recurrent Advanced Aggressive Non-Hodgkin's Lymphoma (NHL)

Phase 1

Completed

Conditions: Lymphoma

First Posted Date: 2005-10-21

Last Posted Date: 2024-12-20

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 41

Registration Number: NCT00243087

Locations: 🇺🇸
UNMC Eppley Cancer Center at the University of Nebraska Medical Center, Omaha, Nebraska, United States
🇺🇸
M. D. Anderson Cancer Center at University of Texas, Houston, Texas, United States
🇺🇸
James P. Wilmot Cancer Center at University of Rochester Medical Center, Rochester, New York, United States

and more 1 locations

Trial to Compare the Effects of Either Telmisartan (40-80 mg PO Once Daily) or Ramipril (5-10 mg PO Once Daily) on Renal Endothelial Dysfunction in Hypertensive Patients With Type 2 Diabetes

Phase 4

Completed

Conditions: Diabetes Mellitus, Type 2
Hypertension

First Posted Date: 2005-10-18

Last Posted Date: 2013-11-08

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 96

Registration Number: NCT00240422

Locations: 🇩🇪
Boehringer Ingelheim Investigational Site, Nürnberg, Germany
🇩🇪
Friedrich-Alexander-Universität, Erlangen, Germany
🇩🇪
Universität Erlangen-Nürnberg, Nürnberg, Germany

and more 1 locations

A Randomized, Double-blind, Placebo Controlled Comparison of Telmisartan Hydrochlorothiazide (HCT) and Valsartan HCT in Hypertension (HTN) Stage I/II Patients

Phase 4

Completed

Conditions: Hypertension

First Posted Date: 2005-10-18

Last Posted Date: 2013-11-05

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1109

Registration Number: NCT00240448

Locations: 🇺🇸
Christopher Chappel, MD, Kissimmee, Florida, United States
🇺🇸
Attention: Larry I. Gilderman, D.O., Pembroke Pines, Florida, United States
🇺🇸
Treasure Valley Cardiology, Boise, Idaho, United States

and more 19 locations

Randomized Single-blind Placebo Controlled Comparative Trial of Pramipexole and Bromocriptine in Parkinson's Disease

Phase 3

Completed

Conditions: Parkinson Disease

First Posted Date: 2005-10-18

Last Posted Date: 2013-11-03

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 208

Registration Number: NCT00240409

Locations: 🇨🇳
First Hospital of Beijing University, Beijing, China
🇨🇳
Beijing Hospital, Beijing, China
🇨🇳
Peking Union Medical College Hospital, Beijing, China

and more 4 locations

A Comparison of Telmisartan + Hydrochlorothiazide With Amlodipine + Hydrochlorothiazide in the Control of Blood Pressure in Older Patients With Predominantly Systolic Hypertension (ATHOS Study)

Phase 4

Completed

Conditions: Hypertension

First Posted Date: 2005-10-18

Last Posted Date: 2013-11-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1000

Registration Number: NCT00240474

Locations: 🇫🇮
Hämeenlinnan lääkäriasema Oy, Linnan klinikka, Hämeenlinna, Finland
🇫🇮
Kouvolan lääkäriasema, Kouvola, Finland
🇫🇮
Hatanpään terveyskeskussairaala, Tampere, Finland

and more 22 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy